PGEN
Precigen, Inc. · Healthcare
4.08
2.74%(-0.12)
Market OpenLast Updated: — ET
52W L: $1.1252W H: $5.47
$4.07
CHG+0.65 (+19.06%)
H$4.25
L$2.75
VOL73M
PGEN (1h)
Precigen, Inc. · Healthcare
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis (RRP) and other diseases, is making progress on that front, announcing it has seen "robust uptake" in usage of PAPZIMEOS (zopapogene imadenovec-drba), since launching the immunotherapy in August 2025. What's more, the company announced that the Centers for Medicare & Medicaid Services (CMS) assigned J-code J3404 to the therapy effective April 1, 2026, which will streamline reimbursement and broaden access to the treatment.
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, of Precigen, will participate in a virtual fireside chat with H.C.
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) gapped up prior to trading on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $9.00. The stock had previously closed at $3.10, but opened at $4.07. Citizens Jmp currently has a market outperform rating on the stock. Precigen shares last traded at
Precigen maintains a Buy rating as Papzimeos' strong launch and FDA approval signal blockbuster potential, with Q1 revenues expected to exceed $18M. PGEN's management guides for cash flow breakeven in 2026, supported by robust payer acceptance and a Q1 revenue run rate over $70M. Scenario analysis yields a probability-weighted fair value of $6.13/share, over 50% above current levels, with a base case fair value of $7.01/share.
Precigen, Inc. (NASDAQ: PGEN) reported mixed results for the fourth quarter on Wednesday.
KIRK RANDAL J
director, 10 percent owner:
1,108,998 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
2,334,420 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
426,199 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
370,847 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
152,063 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
168,794 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
47,101 SH @ $3.30
2026-03-30
KIRK RANDAL J
director, 10 percent owner:
50,797 SH @ $3.30
2026-03-30